CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation

Max J. Gordon, Paul Tardi, Marc Loriaux, Stephen Spurgeon, Elie Traer, Tibor Kovacsovics, Lawrence D. Mayer, Jeffrey Tyner

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose Identify AML patients most likely to respond to CPX-351, a nano-scale liposome formulation containing cytarabine and daunorubicin co-encapsulated at a 5:1 molar ratio. Methods We examined the ex vivo cytotoxic activity of CPX-351 against leukemic cells isolated from 53 AML patients and an additional 127 samples including acute lymphoblastic leukemia, myelodysplastic syndrome/myeloproliferative neoplasms, or chronic lymphocytic leukemia/lymphoma. We assessed activity with respect to common molecular lesions and used flow cytometry to assess CPX-351 cellular uptake. Results AML specimen sensitivity to CPX-351 was similar across conventional risk groups. FLT3-ITD cases were five-fold more sensitive to CPX-351. CPX-351 was active across other indications with nearly all cases exhibiting IC50 values markedly lower than reported 72-h plasma drug concentration in patients receiving CPX-351. The range and distribution of CPX-351 IC50 values were comparable for AML, CLL, and ALL, whereas MDS/MPN cases were less sensitive. CPX-351 uptake analysis revealed a correlation between uptake of CPX-351 and cytotoxic potency. Conclusions Our findings are consistent with clinical data, in which CPX-351 activity is retained in high-risk AML patients. Ex vivo analysis of cytotoxic potency may provide a means to identify specific AML subsets, such as FLT3-ITD, that benefit most from CPX-351 and warrant additional clinical evaluation.

Original languageEnglish (US)
Pages (from-to)39-49
Number of pages11
JournalLeukemia Research
Volume53
DOIs
StatePublished - Feb 1 2017

Fingerprint

Mutation
B-Cell Chronic Lymphocytic Leukemia
Inhibitory Concentration 50
Daunorubicin
Myelodysplastic Syndromes
Cytarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Liposomes
Flow Cytometry
Pharmaceutical Preparations
Neoplasms

Keywords

  • CPX-351
  • Cytarabine
  • Cytotoxicity
  • Daunorubicin
  • Leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. / Gordon, Max J.; Tardi, Paul; Loriaux, Marc; Spurgeon, Stephen; Traer, Elie; Kovacsovics, Tibor; Mayer, Lawrence D.; Tyner, Jeffrey.

In: Leukemia Research, Vol. 53, 01.02.2017, p. 39-49.

Research output: Contribution to journalArticle

@article{de7fbbc2df194c318ae73b76c7082738,
title = "CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation",
abstract = "Purpose Identify AML patients most likely to respond to CPX-351, a nano-scale liposome formulation containing cytarabine and daunorubicin co-encapsulated at a 5:1 molar ratio. Methods We examined the ex vivo cytotoxic activity of CPX-351 against leukemic cells isolated from 53 AML patients and an additional 127 samples including acute lymphoblastic leukemia, myelodysplastic syndrome/myeloproliferative neoplasms, or chronic lymphocytic leukemia/lymphoma. We assessed activity with respect to common molecular lesions and used flow cytometry to assess CPX-351 cellular uptake. Results AML specimen sensitivity to CPX-351 was similar across conventional risk groups. FLT3-ITD cases were five-fold more sensitive to CPX-351. CPX-351 was active across other indications with nearly all cases exhibiting IC50 values markedly lower than reported 72-h plasma drug concentration in patients receiving CPX-351. The range and distribution of CPX-351 IC50 values were comparable for AML, CLL, and ALL, whereas MDS/MPN cases were less sensitive. CPX-351 uptake analysis revealed a correlation between uptake of CPX-351 and cytotoxic potency. Conclusions Our findings are consistent with clinical data, in which CPX-351 activity is retained in high-risk AML patients. Ex vivo analysis of cytotoxic potency may provide a means to identify specific AML subsets, such as FLT3-ITD, that benefit most from CPX-351 and warrant additional clinical evaluation.",
keywords = "CPX-351, Cytarabine, Cytotoxicity, Daunorubicin, Leukemia",
author = "Gordon, {Max J.} and Paul Tardi and Marc Loriaux and Stephen Spurgeon and Elie Traer and Tibor Kovacsovics and Mayer, {Lawrence D.} and Jeffrey Tyner",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.leukres.2016.12.002",
language = "English (US)",
volume = "53",
pages = "39--49",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation

AU - Gordon, Max J.

AU - Tardi, Paul

AU - Loriaux, Marc

AU - Spurgeon, Stephen

AU - Traer, Elie

AU - Kovacsovics, Tibor

AU - Mayer, Lawrence D.

AU - Tyner, Jeffrey

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose Identify AML patients most likely to respond to CPX-351, a nano-scale liposome formulation containing cytarabine and daunorubicin co-encapsulated at a 5:1 molar ratio. Methods We examined the ex vivo cytotoxic activity of CPX-351 against leukemic cells isolated from 53 AML patients and an additional 127 samples including acute lymphoblastic leukemia, myelodysplastic syndrome/myeloproliferative neoplasms, or chronic lymphocytic leukemia/lymphoma. We assessed activity with respect to common molecular lesions and used flow cytometry to assess CPX-351 cellular uptake. Results AML specimen sensitivity to CPX-351 was similar across conventional risk groups. FLT3-ITD cases were five-fold more sensitive to CPX-351. CPX-351 was active across other indications with nearly all cases exhibiting IC50 values markedly lower than reported 72-h plasma drug concentration in patients receiving CPX-351. The range and distribution of CPX-351 IC50 values were comparable for AML, CLL, and ALL, whereas MDS/MPN cases were less sensitive. CPX-351 uptake analysis revealed a correlation between uptake of CPX-351 and cytotoxic potency. Conclusions Our findings are consistent with clinical data, in which CPX-351 activity is retained in high-risk AML patients. Ex vivo analysis of cytotoxic potency may provide a means to identify specific AML subsets, such as FLT3-ITD, that benefit most from CPX-351 and warrant additional clinical evaluation.

AB - Purpose Identify AML patients most likely to respond to CPX-351, a nano-scale liposome formulation containing cytarabine and daunorubicin co-encapsulated at a 5:1 molar ratio. Methods We examined the ex vivo cytotoxic activity of CPX-351 against leukemic cells isolated from 53 AML patients and an additional 127 samples including acute lymphoblastic leukemia, myelodysplastic syndrome/myeloproliferative neoplasms, or chronic lymphocytic leukemia/lymphoma. We assessed activity with respect to common molecular lesions and used flow cytometry to assess CPX-351 cellular uptake. Results AML specimen sensitivity to CPX-351 was similar across conventional risk groups. FLT3-ITD cases were five-fold more sensitive to CPX-351. CPX-351 was active across other indications with nearly all cases exhibiting IC50 values markedly lower than reported 72-h plasma drug concentration in patients receiving CPX-351. The range and distribution of CPX-351 IC50 values were comparable for AML, CLL, and ALL, whereas MDS/MPN cases were less sensitive. CPX-351 uptake analysis revealed a correlation between uptake of CPX-351 and cytotoxic potency. Conclusions Our findings are consistent with clinical data, in which CPX-351 activity is retained in high-risk AML patients. Ex vivo analysis of cytotoxic potency may provide a means to identify specific AML subsets, such as FLT3-ITD, that benefit most from CPX-351 and warrant additional clinical evaluation.

KW - CPX-351

KW - Cytarabine

KW - Cytotoxicity

KW - Daunorubicin

KW - Leukemia

UR - http://www.scopus.com/inward/record.url?scp=85007018242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007018242&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.12.002

DO - 10.1016/j.leukres.2016.12.002

M3 - Article

C2 - 28013106

AN - SCOPUS:85007018242

VL - 53

SP - 39

EP - 49

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -